Cargando…

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

BACKGROUND: The role of adjuvant chemotherapy and the value of molecular biomarkers in bladder cancer have not been determined. We aimed to assess the predictive and prognostic values of excision repair cross-complementation 1 (ERCC1) in identifying appropriate patients who may potentially benefit f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Jong-Mu, Sung, Ji-Youn, Park, Se Hoon, Kwon, Ghee Young, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Jo, Jisuk, Choi, Han Yong, Lim, Ho Yeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404914/ https://www.ncbi.nlm.nih.gov/pubmed/22616552 http://dx.doi.org/10.1186/1471-2407-12-187

Ejemplares similares

Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
por: Lee, Ji Yun, et al.
Publicado: (2017)

Role of Adjuvant Chemotherapy in Advanced Stage Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: Competing Risk Analysis after Propensity Score-Matching
por: Kang, Minyong, et al.
Publicado: (2019)

ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Baek, Moo-Jun
Publicado: (2015)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Efficacy and Safety of Hexaminolevulinate Fluorescence Cystoscopy in the Diagnosis of Bladder Cancer
por: Lee, Jae Seung, et al.
Publicado: (2012)

Conditional Intravesical Recurrence-Free Survival Rate After Radical Nephroureterectomy With Bladder Cuff Excision for Upper Tract Urothelial Carcinoma
por: Chung, Jae Hoon, et al.
Publicado: (2021)

Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
por: Song, Wan, et al.
Publicado: (2016)

Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)

Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
por: Bae, Hoyoung, et al.
Publicado: (2022)

New transperineal ultrasound-guided biopsy for men in whom PSA is increasing after Miles’ operation
por: Park, Byung Kwan, et al.
Publicado: (2023)

Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2
por: Park, Bong Hee, et al.
Publicado: (2016)

Utility of Contemporary Health Screening in the Diagnosis of Bladder Cancer
por: Lee, Chung-Un, et al.
Publicado: (2022)

Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients
por: Yoon, Nara, et al.
Publicado: (2017)

Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma
por: Ryoo, Hyunsoo, et al.
Publicado: (2021)

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()
por: Jang, Jiryeon, et al.
Publicado: (2017)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Genomic Sequencing for Bladder Urothelial Carcinoma and Its Clinical Implications for Immunotherapy
por: Kim, Ryul, et al.
Publicado: (2022)

The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development
por: Rouissi, Kamel, et al.
Publicado: (2011)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023)

Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
por: Kang, Minyong, et al.
Publicado: (2020)

A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma
por: Jo, Hyunji, et al.
Publicado: (2022)

The clinical utility of transperineal template-guided saturation prostate biopsy for risk stratification after transrectal ultrasound-guided biopsy
por: Song, Wan, et al.
Publicado: (2019)

A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
por: Kim, Hae Su, et al.
Publicado: (2017)

Influence of Body Mass Index, Smoking, and Blood Pressure on Survival of Patients with Surgically-Treated, Low Stage Renal Cell Carcinoma: A 14-Year Retrospective Cohort Study
por: Park, Bumsoo, et al.
Publicado: (2013)

Pure Laparoscopic Radical Cystectomy with Ileal Conduit: A Single Surgeon's Mid-Term Outcomes
por: Park, Bumsoo, et al.
Publicado: (2013)

The use of adjuvants to local anesthetics: benefit and risk
por: Jeon, Young Hoon
Publicado: (2018)

A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
por: Byeon, Seonggyu, et al.
Publicado: (2021)

Outcome of Prostate Biopsy in Men Younger than 40 Years of Age with High Prostate-Specific Antigen (PSA) Levels
por: Yang, Jin Bak, et al.
Publicado: (2010)

Incidence and Predictive Factors of Benign Renal Lesions in Korean Patients with Preoperative Imaging Diagnoses of Renal Cell Carcinoma
por: Park, Seo Yong, et al.
Publicado: (2011)

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
por: Park, Seong Yong, et al.
Publicado: (2023)

Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance
por: Choo, Seol Ho, et al.
Publicado: (2014)

Diagnostic and Prognostic Significance of Radiologic Node-positive Renal Cell Carcinoma in the Absence of Distant Metastases: A Retrospective Analysis of Patients Undergoing Nephrectomy and Lymph Node Dissection
por: Lee, Hye Won, et al.
Publicado: (2015)

Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges
por: Lee, Hye Won, et al.
Publicado: (2015)

Is Radical Perineal Prostatectomy a Viable Therapeutic Option for Intermediate- and High-risk Prostate Cancer?
por: Lee, Hye Won, et al.
Publicado: (2015)

Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
por: Choi, Young Hyo, et al.
Publicado: (2019)

Predictive Preoperative Factors for Renal Insufficiency in Patients Followed for More Than 5 Years After Radical Nephrectomy
por: Ahn, Joong Seo, et al.
Publicado: (2013)

Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5–10 ng/mL
por: Choi, Joongwon, et al.
Publicado: (2020)

Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma
por: Yoo, Gyu Sang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55689lt90ptq49qhke03cl9a54